ACE Inhibitor or ARB as First-Line Therapy
For this 40-year-old man with new-onset stage 1 hypertension (BP 142-146/86-98 mm Hg), an ACE inhibitor (such as lisinopril 2.5-5 mg daily) or ARB (such as losartan 25-50 mg daily) is the ideal first-line antihypertensive agent. Given his complex medication regimen including quetiapine (which increases hyperlipidemia risk) and multiple psychotropic medications, a renin-angiotensin system (RAS) blocker offers the best balance of efficacy, tolerability, and minimal drug interactions 1, 2.
Rationale for RAS Blocker Selection
Guideline-Based First-Line Options
According to Hypertension Canada 2020 guidelines, first-line monotherapy options for uncomplicated hypertension in patients under 60 include 2:
- Thiazide/thiazide-like diuretics (Grade A)
- ACE inhibitors in non-black patients (Grade B)
- Long-acting calcium channel blockers (Grade B)
- ARBs (Grade B)
- β-blockers in patients <60 years (Grade B)
The 2024 ESC guidelines similarly endorse ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazides as first-line agents with demonstrated CVD event reduction 3.
Why RAS Blockers Are Optimal Here
Metabolic neutrality: Unlike thiazide diuretics, ACE inhibitors and ARBs do not cause hypokalemia or worsen metabolic parameters—critical given his hyperlipidemia and quetiapine therapy (which already increases dyslipidemia risk) 4, 5. Quetiapine is associated with relatively high risk for hyperlipidemia, making metabolically neutral antihypertensives preferable.
Drug interaction profile: ACE inhibitors and ARBs have minimal interactions with his extensive psychotropic regimen (gabapentin, tramadol, trazodone, buspirone, quetiapine, brexpiprazole). In contrast:
- Thiazide diuretics require monitoring for hypokalemia, which could be problematic with quetiapine (which can cause QT prolongation)
- Calcium channel blockers may exacerbate peripheral edema (gabapentin already causes this as a common side effect)
- β-blockers are NOT recommended as first-line in patients <60 years per guidelines 1, 2
Tolerability with polypharmacy: This patient takes 9 medications. ACE inhibitors/ARBs have straightforward dosing (once daily), predictable side effect profiles, and won't compound sedation or orthostatic hypotension risks from his psychotropic medications.
Specific Agent Recommendations
ACE Inhibitor Option
Lisinopril 2.5-5 mg once daily is preferred because:
- Once-daily dosing improves adherence in polypharmacy patients
- No active metabolites requiring hepatic metabolism (important given potential drug interactions)
- Well-established safety profile
- Can titrate to 20-40 mg daily if needed 6
ARB Alternative
Losartan 25-50 mg once daily if ACE inhibitor causes cough:
- Lower risk of angioedema compared to ACE inhibitors
- Similar efficacy for BP control
- Once-daily dosing
- Can titrate to 50-100 mg daily 6
Critical Monitoring Considerations
Baseline and Follow-up Labs
- Serum creatinine and potassium at baseline and 1-2 weeks after initiation
- Renal function monitoring is essential given potential gabapentin accumulation with renal impairment (gabapentin is renally cleared and can cause serious toxicity including rhabdomyolysis with accumulation) 7
Blood Pressure Targets
- Target BP <140/90 mm Hg per Canadian guidelines 2
- The 2025 AHA/ACC guidelines suggest <130/80 mm Hg for most adults, but given his complex medication regimen and potential for orthostatic effects from psychotropics, a more conservative initial target of <140/90 is reasonable 8
Titration Strategy
- Start with low-dose monotherapy (lisinopril 2.5-5 mg or losartan 25-50 mg)
- Reassess BP in 2-4 weeks
- If BP remains >140/90 mm Hg, either:
Important Caveats
Avoid β-Blockers
β-blockers are NOT recommended as first-line therapy in patients <60 years with uncomplicated hypertension (Grade A) 1, 2, 1. This patient is 40 years old with no compelling indication (no heart failure, post-MI, or angina).
Combination Therapy Contraindication
Never combine ACE inhibitor + ARB (Grade A recommendation against this combination due to increased adverse events without additional benefit) 1, 2, 6, 3.
Gabapentin Safety Concerns
Monitor for gabapentin-related complications including:
- Hypoglycemia (rare but reported, especially in elderly or those with pre-diabetes) 9
- Rhabdomyolysis risk, particularly with polypharmacy and renal impairment 7
- Respiratory depression when combined with CNS depressants (tramadol, trazodone, quetiapine) 10
Quetiapine-Related Considerations
The FDA label for quetiapine warns about orthostatic hypotension as a significant adverse effect 11. When initiating antihypertensive therapy:
- Start with low doses to minimize additive hypotensive effects
- Counsel patient on fall risk (quetiapine causes somnolence, postural hypotension, and motor instability)
- Monitor standing and sitting BP at follow-up visits
Barrett's Esophagus Management
His omeprazole 40 mg BID is appropriate for Barrett's esophagus management 12, 13. This does not influence antihypertensive choice, as PPIs have minimal interactions with RAS blockers.
If Initial Therapy Fails
Should BP remain uncontrolled on maximally tolerated ACE inhibitor or ARB monotherapy:
- Add a thiazide-like diuretic (chlorthalidone 12.5-25 mg daily or indapamide 1.25-2.5 mg daily) - Grade B evidence for combination 1, 2
- Alternative: Add long-acting dihydropyridine CCB (amlodipine 2.5-10 mg daily) - Grade C evidence for ACE inhibitor + CCB combination 1
- Monitor potassium carefully if adding thiazide (avoid hypokalemia which could interact with quetiapine's cardiac effects)
The 2025 AHA/ACC guidelines support initial combination therapy for stage 2 hypertension (BP ≥140/90), ideally as single-pill combinations to improve adherence 8. However, given this patient's extensive polypharmacy and orthostatic risk from psychotropics, starting with monotherapy and titrating carefully is more prudent.